The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD)

Publications

Ouakidi D, Bourouis BN, Banat MA, Azzi N, Benzait S, Snouber A

Secondary Organising Pneumonia Caused by Denosumab.

European journal of case reports in internal medicine 2023;10;004043 — 2023 — 004043

Ruiz AC, Carrascosa MF, Concha ST, Gil AH, Rivero JG

Interstitial Lung Disease in a Patient Treated with Denosumab.

European journal of case reports in internal medicine 2019;6;001131 — 2019 — 001131